PharmaTher Secures U.S. Patent for Ketamine in ALS, Strengthening Market Position

PharmaTher Holdings Ltd ( (TSE:PHRM) ) just unveiled an announcement.

PharmaTher Holdings Ltd. has secured a key U.S. patent for the use of ketamine in treating Amyotrophic Lateral Sclerosis (ALS), enhancing its Orphan Drug Designated Program. This development strengthens the company’s intellectual property portfolio and positions it strategically within the ALS treatment market, which is projected to exceed $1.04 billion by 2030. The patent, alongside the FDA’s Orphan Drug Designation, provides PharmaTher with a significant competitive edge, offering long-term patent protection and market exclusivity. The company is advancing its clinical program with plans for a Phase 2 study and aims to maximize the commercial potential of ketamine for ALS, addressing a critical unmet medical need.

Spark’s Take on TSE:PHRM Stock

According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.

PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.

To see Spark’s full report on TSE:PHRM stock, click here.

More about PharmaTher Holdings Ltd

PharmaTher Holdings Ltd. is a company focused on the research and commercialization of KETARX™ (Ketamine) to address unmet medical needs in surgery, pain, mental health, neurological, and medical countermeasures indications.

Average Trading Volume: 56,796

Technical Sentiment Signal: Buy

Current Market Cap: C$28.33M

For detailed information about PHRM stock, go to TipRanks’ Stock Analysis page.